Literature DB >> 18313578

Qualitative radiology assessment of tumor response: does it measure up?

Ronald H Gottlieb1, Alan Litwin, Bhavna Gupta, John Taylor, Cheryl Raczyk, Terry Mashtare, Gregory Wilding, Marwan Fakih.   

Abstract

Our purpose was to assess whether a simpler qualitative evaluation of tumor response by computed tomography is as reproducible and predictive of clinical outcome as the Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) methods. This study was a two-reader retrospective evaluation in which qualitative assessment resulted in agreement in 21 of 23 patients with metastatic colorectal carcinoma (91.3%, kappa=0.78; 95% CI, 0.51-1.00). Hepatic metastases were classified as increased, decreased, or unchanged, compared with agreement in 20 of 23 patients (87.0%) for RECIST (kappa=0.62; 95% CI, 0.23-1.00) and WHO (kappa=0.67; 95% CI, 0.34-1.00) methods. Patients were placed into partial response, stable disease, and disease progression categories. Time to progression of disease was better predicted qualitatively than by RECIST or WHO. Our pilot data suggest that our qualitative scoring system is more reproducible and predictive of patient clinical outcome than the RECIST and WHO methods.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313578     DOI: 10.1016/j.clinimag.2007.11.001

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  2 in total

1.  Quantified visual scoring of metastatic melanoma patient treatment response using computed tomography: improving on the current standard.

Authors:  Ronald H Gottlieb; Elizabeth Krupinski; Pavani Chalasani; Lee Cranmer
Journal:  J Digit Imaging       Date:  2012-04       Impact factor: 4.056

2.  Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.

Authors:  Sucheta Telang; Mary Ann Rasku; Amy L Clem; Karen Carter; Alden C Klarer; Wesley R Badger; Rebecca A Milam; Shesh N Rai; Jianmin Pan; Hana Gragg; Brian F Clem; Kelly M McMasters; Donald M Miller; Jason Chesney
Journal:  BMC Cancer       Date:  2011-12-13       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.